Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S5 - E9.5 - In-Office Screening Post-Rezdiffra: The Importance Of Predictive Biomarkers
Description: This conversation focuses on how the need for biomarkers will evolve in an era of in-office screening and MASH drugs and ends with answers to Roger Green's closing question. Hannes Hagstrom starts this conversation by noting that one challenge as MASH drugs become available involves knowing when to discontinue or add to therapy since, as he points out, Rezdiffra will not be efficacious for all patients. This leads Jörn Schattenberg to the need for predictive biomarkers that will be specific to drugs or modes of action. These have not been studied much to date. Jörn is...